Status: Recruiting
Avutometinib and Defactinib in Diffuse Gastric Cancer
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Participants needed: 27
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Ryan H. Moy, MD, PhDUpdated: Nov 4, 2025Locations: 1
Eligibility criteria
Histologic or cytologic evidence of gastric/gastroesophageal junction carcinoma,... [+9]
Systemic anti-cancer therapy within 3 weeks of the first dose of study therapy,... [+21]